The purpose of this clinical study is to find out if NNC0497-0040 is safe, tolerable and effective for healthy people living with normal weight or overweight, people living with overweight or obesity and people who have type 1 diabetes and are living with overweight or obesity. There are 2 study treatments in this study, where participants will get either NNC0497-0040, the new treatment being tested or placebo, a treatment that has no active medicine in it. Participants will be in this clinical study for up to 29 weeks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of adverse events
Timeframe: Day 1 up to Week 6
Number of adverse events
Timeframe: MAD1-2: Day 1 up to Week 17; MAD3: Day 1 up to Week 25
Number of adverse events
Timeframe: Day 1 up to Week 25